Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
Netherlands
In shortRedcare Pharmacy N.v. is loss-making, burns cash and carries moderate debt, with revenue growing (+24.1% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -1.0% | 13/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -1.3% | 15/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -8.0% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -3.0% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.55× | 62/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.72× | 71/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | 5.02× | 0/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | -0.91× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | – | n/a |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -1.6% | 13/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 2 of 5 | 25/100 |
Weight in the score: 20%
| Profitable years (last 5) | 0 of 5 | 0/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 5 | 100/100 |
| Revenue growth volatility | 15.9% | 52/100 |
| Operating margin volatility | 2.6% | 85/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 34.7% | 100/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
European data comes from annual reports in ESEF format (since 2020). Industry and ticker are not provided by this source.
Annual figures as reported. Hover a bar or point for the exact value.
1 older year available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
EUR millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 1,060 | 1,204 | 1,799 | 2,371 | 2,941 |
| Cost of revenue | 794 | 873 | 1,358 | 1,825 | 2,278 |
| Gross profit | 267 | 332 | 440 | 546 | 663 |
| Operating income | (66) | (69) | (17) | (39) | (29) |
| Interest expense | 13 | 17 | 16 | 17 | 31 |
| Pre-tax income | (78) | (84) | (14) | (48) | (48) |
| Income tax | (3.7) | (6.5) | (2.7) | (1.5) | (8.3) |
| Net income | (74) | (78) | (12) | (46) | (38) |
| Diluted EPS | −€4.15 | −€4.32 | −€0.73 | −€2.27 | −€1.87 |
1 older year available with the 10-year history. Essential plan, from €8.25/month →
Not computed: a required balance-sheet item is missing.
4/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: filings.xbrl.org (ESEF). Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice.
Latest annual report: Dec 31, 2025 · Data updated Mar 18, 2026